- Home
- ZVSA vs RSLS Comparison
ZVSA vs RSLS Comparison
Compare ZVSA & RSLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- RSLS
- Stock Information
- Founded
- ZVSA 2014
- RSLS 2002
- Country
- ZVSA United States
- RSLS United States
- Employees
- ZVSA N/A
- RSLS N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- RSLS Medical/Dental Instruments
- Sector
- ZVSA Health Care
- RSLS Health Care
- Exchange
- ZVSA Nasdaq
- RSLS Nasdaq
- Market Cap
- ZVSA 3.5M
- RSLS 3.2M
- IPO Year
- ZVSA N/A
- RSLS 2007
- Fundamental
- Price
- ZVSA $1.22
- RSLS $1.12
- Analyst Decision
- ZVSA Strong Buy
- RSLS Hold
- Analyst Count
- ZVSA 1
- RSLS 1
- Target Price
- ZVSA $240.00
- RSLS N/A
- AVG Volume (30 Days)
- ZVSA 69.7K
- RSLS 2.6M
- Earning Date
- ZVSA 03-24-2025
- RSLS 03-31-2025
- Dividend Yield
- ZVSA N/A
- RSLS N/A
- EPS Growth
- ZVSA N/A
- RSLS N/A
- EPS
- ZVSA N/A
- RSLS N/A
- Revenue
- ZVSA N/A
- RSLS $8,183,000.00
- Revenue This Year
- ZVSA N/A
- RSLS $17.47
- Revenue Next Year
- ZVSA N/A
- RSLS $20.00
- P/E Ratio
- ZVSA N/A
- RSLS N/A
- Revenue Growth
- ZVSA N/A
- RSLS N/A
- 52 Week Low
- ZVSA $0.98
- RSLS $1.01
- 52 Week High
- ZVSA $25.00
- RSLS $29.00
- Technical
- Relative Strength Index (RSI)
- ZVSA 44.26
- RSLS 19.11
- Support Level
- ZVSA $1.12
- RSLS $1.01
- Resistance Level
- ZVSA $1.29
- RSLS $1.85
- Average True Range (ATR)
- ZVSA 0.09
- RSLS 0.35
- MACD
- ZVSA -0.01
- RSLS -0.18
- Stochastic Oscillator
- ZVSA 37.04
- RSLS 3.99
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.